<DOC>
	<DOCNO>NCT01969266</DOCNO>
	<brief_summary>The purpose study examine exposure safety supratherapeutic dose PCI-32765 ( ibrutinib ) healthy adult volunteer .</brief_summary>
	<brief_title>A Pharmacokinetic Study Healthy Participants Assess Pharmacokinetics Safety Supratherapeutic Dose PCI-32765 ( Ibrutinib ) Capsule Solution Formulations Administered With Food</brief_title>
	<detailed_description>This open-label ( identity assign study drug know ) , 2-period , sequential , exploratory study healthy adult men woman determine exposure safety supratherapeutic dose PCI-32765 ( ibrutinib ) capsule solution formulation administer food . Eight participant ( include least 2 woman ) enrol receive 2 treatment : PCI-32765 840 mg administer capsule ( Treatment A Period 1 ) solution ( Treatment B Period 2 ) formulation . All participant receive treatment 7-day washout period dos . A high-fat breakfast provide 2 hour dose . Serial pharmacokinetic ( study body drug ) sample collect dose 72 hour dose safety monitor throughout study . The total duration study approximately 46 day .</detailed_description>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Women must postmenopausal surgically sterile A sexually active man woman childbearing potential vasectomy must agree use adequate contraception method study 3 month receive last dose study drug , donate sperm study 3 month receive last dose study drug Body mass index 18 30 kg/m2 body weight less 50 kg Blood pressure ( sit 5 minute ) 90 140 mmHg systolic , high 90 mmHg diastolic 12lead ECG consistent normal cardiac conduction function Nonsmoker History current clinically significant medical illness include ( limited ) cardiac arrhythmia cardiac disease , hematologic disease , coagulation disorder , lipid abnormality , significant pulmonary disease , include bronchospastic respiratory disease , diabetes mellitus , renal hepatic insufficiency , thyroid disease , neurologic psychiatric disease , infection , history immune disorder , illness investigator considers exclude participant could interfere interpretation study result Clinically significant abnormal value hematology , coagulation , PFA 100 , clinical chemistry , urinalysis screen admission study center deem appropriate investigator Use prescription nonprescription medication ( include vitamin herbal supplement ) , except acetaminophen , hormonal replacement therapy within 14 day first dose study drug schedule Use herbal supplement St. John 's Wort within 30 day first study drug administration History drug alcohol abuse accord Diagnostic Statistical Manual Mental Disorders ( 4th edition ) ( DSMIV ) criterion within 2 year screen positive test result ( ) alcohol and/or drug abuse screen Day 1 treatment period History clinically significant allergy , especially know hypersensitivity intolerance sulfonamide betalactam antibiotic Known allergy study drug excipients formulation Donated blood blood product substantial loss blood ( 500 mL ) within 3 month first administration study drug intention donate blood blood product study Received experimental drug use experimental medical device within 1 month within period le 10 time drug 's halflife , whichever longer , first dose study drug schedule Unable swallow solid , oral dosage form whole aid water A woman pregnant , breastfeed plan become pregnant study A man plan father child enrol study within 3 month last dose study drug Positive test human immunodeficiency virus 1 2 antibody , hepatitis B surface antigen , hepatitis C antibodies History smoking use nicotinecontaining substance within previous 2 month , positive cotinine test screening Preplanned surgery procedure would interfere conduct study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Healthy volunteer</keyword>
	<keyword>PCI-32765</keyword>
	<keyword>PCI 45227</keyword>
	<keyword>JNJ-54179060</keyword>
	<keyword>Pharmacokinetic</keyword>
</DOC>